Compare Adaptive Biotechnologies Corp (ADPT) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.64. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | EMB | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Fixed Income |
52-Week High | $22.37 | $97.74 |
52-Week Low | $10.24 | $91.52 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EMB trades at $96.35, showing minimal daily movement with a 0.16% gain. The technical outlook is neutral, supported by a bullish moving average signal but offset by neutral oscillators and sell signals from the ADX. Recent corporate actions include scheduled dividend payments in 2026, though key financial ratios are unavailable for fundamental assessment.
The outlook for EMB hinges on emerging market bond dynamics and Federal Reserve policy, with news highlighting yield appeal but also sovereign default risks. Key risks include geopolitical tensions and inflation, while institutional interest in EM bond ETFs suggests underlying demand. Investors should weigh high-yield potential against macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
